Measuring the process of care rather than merely outcomes is an alternative approach to assess overall quality of care.
valuation of quality of care has become an integral part of modern health care and provides key information for health authorities, health insurance providers, patients, the general public, and physicians themselves. Among the factors that can influence the quality of care, hospital case volume has drawn considerable attention. Indeed, as early as the 1980s, a relationship between volume of activity and mortality was described, and it exists not only in certain surgical procedures but also in medical conditions such as myocardial infarction, acute heart failure, or pneumonia. 1, 2 However, the relationship between volume and quality of care is complex and is characterized by wide variations in mortality between the different levels of volume. When quality of care is assessed by rare outcomes such as death, the measure of volume-quality of care relationship is difficult in centers with lower activity. 3 Thus, it may be that zero mortality in a given center could merely be the result of chance rather than a reliable indicator of excellent care. therapy during hospitalization and at discharge, 7 and composite scores. 8 Current guidelines from the European Society of Cardiology recommend that QIs be recorded after AMI with 9 or without 10 ST-segment elevation. In France, the National Authority for Health (Haute Autorité de Santé) has defined specific QIs to evaluate the management of AMI, to benchmark performance, and to follow the evolution of AMI management nationwide from the initial onset of symptoms until 1 year after discharge.
11 Three campaigns to measure these QIs for AMI have been implemented to date, in 2008, 2009 , and 2010, throughout the whole country and in all centers admitting patients for chest pain. The centers participating in the assessment presented wide variation in case volume. Given that the relationship between volume and QIs is less well documented than the volume-mortality relationship, we aimed to use the results of this repeated nationwide assessment to quantify the relationship between volume and QIs in survivors after AMI.
Methods

Selection of Medical Records for Evaluation
In the framework of the national system for accreditation of healthcare centers, the Haute Autorité de Santé decided to define QIs to be measured systematically in all centers. Almost all healthcare centers in France (public and private) participated. The medical records to be evaluated in each center were chosen by random selection of 100 records from among all those with a diagnostic code for AMI with or without ST-segment elevation (International Classification of Diseases, 10th revision codes I21.0, I21.1, I21.2, I21.3, I21.9, I22.0, I22.1, I22.8, I22.9) using specialized randomization software specifically designed for this purpose (LOTAS, available at http://download. atih.sante.fr/afficher.php?id_lot=725). In 2008, records were selected from among the 12 months of the year; in 2009, from among the first 6 months of the year; and in 2010, from among the first 9 months. Only the records of patients discharged alive were analyzed. Records corresponding to patients transferred to or from another center were excluded.
Analysis of prescriptions was performed by an independent med ical team using a computer-based algorithm. The coherence of data was verified by an independent group responsible for performance measurement and improvement in hospitals (Mesure de la Performance et l'Amélioration de la Qualité Hôpital, Patient, Sécurité, Territoire [COMPAQH-HPST]). QIs for AMI were defined by an expert consensus group on myocardial infarction comprising cardiologists and methodologists. QIs were based on the recommendations for management of AMI issued by the European Society of Cardiology 9,10 and on existing performance measures developed and used by the American College of Cardiology/American Heart Association. 7 Details of the QIs can be found on the Web site of the COMPAQH group. 12 Appropriate prescription (AP) was defined as prescription in the absence of any contraindication clearly documented in the patient's file or nonprescription in the presence of a clearly documented contraindication. The following QIs (discharge only) were used without taking doses into account:
• AP of the association of aspirin and clopidogrel. Contraindications to aspirin were intolerance or allergy to aspirin, high risk of bleeding, gastroduodenal ulcer, and pregnancy. Contraindications to clopidogrel were intolerance, high bleeding risk, and pregnancy. High bleeding risk was accepted as justification for nonprescription of aspirin or clopidogrel when the bleeding risk evaluation was clearly documented in the patient's file.
• AP of β-blockers. Two types of contraindication were retained: absolute contraindications (ie, uncontrolled heart failure, hypotension, high-degree atrioventricular block, severe chronic obstructive pulmonary disease or asthma, the Raynaud syndrome, and hypersensitivity). In case of relative contraindications (ie, controlled chronic obstructive pulmonary disease, asthma, diabetes mellitus, first-degree atrioventricular block, and heart failure), a documented evaluation of the risk-benefit ratio had to be present in the file to justify nonprescription.
• Documentation of a measure of left ventricular ejection fraction and, in case of ejection fraction <0.40, AP of an angiotensinconverting enzyme inhibitor (ACEI) or an angiotensin receptor blocker. Contraindications were hypotension or intolerance.
• AP of statins. The only contraindication to statin therapy was intolerance. 13 Odds ratios adjusted for age and sex with 95% confidence intervals for the volume categories were calculated using logistic regression for each QI. Adjusted odds ratios for each volume category were calculated per year and per QI. To account for within-hospital correlation and the hierarchical data structure, we used a PROC GENMOD with the repeated statement. Temporal changes were tested according to the Cochran-Armitage test for binary variables, and only centers that participated in all 3 campaigns were included in this analysis. All analyses were performed with SAS software, version 9.2 (SAS Institute Inc, Cary, NC).
Statistical Analysis
WHAT IS KNOWN
• Higher hospital case volume has been associated with better outcomes for some conditions. • Measuring processes of care rather than outcomes is an alternative approach to assessing overall quality of care.
WHAT THE STUDY ADDS
• We identified a relationship between case volume and the quality of prescriptions of evidence-based therapies for myocardial infarction at hospital discharge, whereby centers with the highest volume perform better on quality measures than centers with lower volumes.
• Temporal analysis over 3 consecutive years confirms this relationship and shows that it persists despite overall improvement in quality indicators between 2008 and 2010.
• The use of a composite indicator based on discharge prescription makes it possible to assess quality in all participating centers, but a minimum of 30 patients per center was required to use the composite for benchmarking purposes.
Results
The (Table 1 and Figure 3) . The test for temporal trend was significant for all QIs (Figure 3 ). The average values for each QI in centers that participated in all 3 campaigns are presented in Table 2 according to year and center volume. Figure 4 displays the age-and sex-adjusted odds ratios per volume category for each QI in each of the 3 years. Compared with a volume of >300 cases, a significantly lower rate of all QIs was observed in centers with the lowest volume ( Table 2 ). In 2008 and 2009, the odds ratios progressively decreased with increasing volume, but no clear plateau was apparent that would support the hypothesis of a threshold (Table 2 and Figure 4 ).
The linear relationship between the composite indicator and volume of activity is shown in Figure 5 and illustrates the wide variation in composite scores, particularly in centers with a low volume of activity.
The temporal change in the relationship between high and low volume (>90 or <90) and the composite QI is displayed in Figure 6 . Despite a significant increase in the composite QI, a significant relationship persisted between volume and quality of care. The time-volume interaction was significant for all QIs except antiplatelet agents and statins.
Discussion
This nationwide study using robust methodology to evaluate quality of care through QIs at hospital discharge in a largescale population demonstrates the existence of a relationship between volume and quality of care in centers treating AMI in France. Indeed, admission to a hospital with a high volume of activity was associated with better performance on QI. This relationship was observed over 3 consecutive years, and although performance on QIs progressed from 2008 to 2010, the difference between high-and low-volume centers persisted.
These findings go beyond previous reports of an association between volume and mortality, which was first established several years ago. 1, 2 These observations suggest that the difference in mortality is truly related to the quality of care. The progression in quality with increasing volume seems linear, without any clear threshold value. This contradicts what has been shown for the volume-mortality association, for which a threshold was seen of >600 cases per year. 2 No such threshold was observed in our national evaluation because few centers reached such a high annual volume. In addition, the use of QIs instead of mortality outcomes and the selection of survivors of the acute phase may explain this discrepancy.
The magnitude of the difference between the highest-and lowest-volume centers in terms of QIs is considerable. In 2008, the absolute value of the difference was ≈10% for AP of aspirin plus clopidogrel and ACEI and up to 15% for statins or the composite measure. Although the differences in the rates of QIs declined in 2009 and 2010, they remain considerably greater than the impact of volume on mortality at 30 days after AMI, which was ≈1% to 4%, 2 even when reperfusion QIs were taken into account. [14] [15] [16] This underlines the greater sensitivity of process-of-care measures compared with outcome measures. It is important to note that the magnitude of the difference in QIs according to volume is comparable to the rate of contraindications recorded for β-blockers or ACEIs. This underlines the importance of recording QI instead of the prescription rate alone, despite the higher complexity and cost that this more complete procedure may incur.
Our results also underscore the existence of heterogeneous quality of care between the volume categories as shown by the very wide confidence intervals around the QI rates and the scattergram plotting the composite indicator against volume of activity, particularly in centers with low volume. Variations in quality of care at different volumes of activity have previously been described in surgical procedures.
1 Excellent measures of quality in low-volume centers may merely reflect difficulties in measurement in these centers 3 or may alternatively be explained by the fact that the physicians' experience has a greater impact on quality than the center's volume of activity, 16, 17 according to the principle that, at a physician level, practice makes perfect.
The strong points of our study are the robust methodology, the use of a composite measure, and the repeated evaluations over 3 consecutive years.
The evaluation of prescriptions at discharge is part of a vast national evaluation program implemented by the French National Authority for Health (Haute Autorité de Santé) in recent years. This program made it possible for all French healthcare centers to participate in the evaluation campaigns, with repeated evaluations over consecutive years, using the same methodology, and accumulating a total of >48 000 admissions evaluated. Although the decision to launch the program was made at the initiative of the national authority for health (an administrative body), the choice of the QIs and related contraindications was made by an expert group of cardiologists. In addition, all data were taken directly from original patient files on site in each center, not from an administrative database. Although large-scale evaluations of this type have previously been performed in other countries, this is the first study to report on a nationwide evaluation, including practically all centers, with random selection of records and without age selection. Furthermore, such a study has never been performed in France to date. Finally, the national social security system covers the total costs of treatment after AMI, which may have limited certain economic biases in prescribing habits at discharge.
Of course, improvement in clinical outcomes remains the ultimate goal of quality-of-care initiatives. However, assessing quality through mortality statistics remains difficult because of the manifold factors involved in this relationship. 18 Measuring processes of care such as QIs presents some advantages over evaluation of mortality as an outcome. In the case of AMI in particular, specific indicators were developed almost 10 years ago and are regularly updated to take into account therapeutic progress. These indicators are based on the use of reperfusion techniques 6 and medical therapy during hospitalization and at discharge. 7 Indeed, current guidelines from the European Society of Cardiology recommend that QIs be recorded after AMI with 9 or without 10 ST-segment elevation. In our study, we used 4 QIs at discharge that are simple to define, have good discriminatory capacity, are based on solid scientific evidence of efficacy, and for which wider use is both possible and beneficial. These characteristics correspond to the basic requirements for accountability measures 19 and are comparable to the QIs used by the American College of Cardiology/American Heart Association, the National Quality Measure Clearinghouse, or the Agency for Healthcare Research and Quality. 7 The latest update of the QIs for reperfusion from the American College of Cardiology/American Heart Association underlined the difficulties associated with the evaluation of reperfusion. 6 The decision not to measure QIs for reperfusion or in-hospital treatment has the advantage of rendering the data collection simple and reliable and makes it possible to evaluate the totality of centers admitting patients for AMI, not just centers equipped with reperfusion facilities.
The use of a composite QI makes it possible to give an overall estimation of quality of care and to classify centers according to performance. 7, 8 Among the different methods of developing composite QIs, we considered the all-or-none method to be most suited to our needs, given that the absence of any one of the QIs included in the composite corresponds to suboptimal management. To account for differences in recruitment or in the random selection of patient files for analysis, we adjusted for age and sex only, which are known to be related to underuse of guideline-recommended therapies. Other types of composite measures are of course possible and, although correlated to the all-or-none method, could lead to different results. 13 Consecutive evaluation over 3 calendar years with the same methodology made it possible not only to increase the number of admissions evaluated but also to gain insight into the temporal evolution of quality of care. Temporal change in treatment and strategies has been studied in different registries as a marker of progressing quality of care, particularly in the case of reperfusion 20, 21 but also in medical therapy [22] [23] [24] with, in parallel, temporal evolution in mortality. [25] [26] [27] The progression in QIs observed over the 3 years of our study is comparable to that observed between 2003 and 2006 in the Joint Commission on Accreditation of Healthcare Organizations and Centers for Medicare and Medicaid Services evaluations. 28, 29 Interestingly, the temporal changes were more pronounced for ACEI and β-blockers than for aspirin, clopidogrel, and statins, perhaps because of the relatively high rate already achieved for these latter prescriptions. In our study, the volume-QI relationship remained constant from 1 year to the next, and when centers were categorized by volume (<90 or >90 admissions per year), there was a trend toward an increase in the difference in quality over time.
Our study suffers from certain limitations inherent to evaluations of quality through measures of processes of care. The exclusive use of QIs at discharge precludes the measure of the quality of reperfusion, which is a key element of management of AMI with ST-segment elevation that contributes to selecting patients who survive the in-hospital phase. In addition, AP of β-blockers and statins does not necessarily imply optimal clinical or biological effect. The lack of any parallel evaluation of mortality precludes the establishment of a link between measures of processes of care and outcome. Furthermore, volume categories were defined on the basis of activity in 2008, and we assumed that activity remained stable in all centers over the 3 years of the evaluation. We cannot exclude the possibility that some centers may have had a different level of volume in 2009 or 2010. Finally, the retrospective nature of the analysis may represent a source of error in the documentation of indications or contraindications of the drugs under evaluation. However, in the context of multiple healthcare providers, accurate documentation of indications and contraindications can be considered part of the quality of care.
Conclusions
Analysis of QIs at discharge demonstrates the existence of a relationship between volume and the quality of prescriptions at discharge whereby centers with the highest volume perform better on quality measures than centers with lower volumes. Temporal analysis over 3 consecutive years confirms this relationship and shows that it persists despite improvement in QIs between 2008 and 2010.
